|
|
Volumn 6, Issue 4, 2007, Pages 258-259
|
|
New HIV drug classes on the horizon
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;
ANTIRETROVIRUS AGENT;
APLAVIROC;
BEVIRIMAT;
CHEMOKINE RECEPTOR CCR5;
CHEMOKINE RECEPTOR CCR5 ANTAGONIST;
CHEMOKINE RECEPTOR CXCR4;
ELVITEGRAVIR;
ETRAVIRINE;
FOSALVUDINE TIDOXIL;
FUSION INHIBITOR;
INCB 9471;
INTEGRASE INHIBITOR;
KP 1212;
LEUKOTRIENE B4 RECEPTOR STIMULATING AGENT;
LEUKOTRIENE RECEPTOR STIMULATING AGENT;
MARAVIROC;
MIFEPRISTONE;
MIV 210;
PROTEINASE INHIBITOR;
RALTEGRAVIR;
RILPIVIRINE;
RNA DIRECTED DNA POLYMERASE INHIBITOR;
S 364735;
TMC 728;
TNX 355;
UNCLASSIFIED DRUG;
VICRIVIROC;
ANTIVIRAL ACTIVITY;
ARTICLE;
CLINICAL TRIAL;
COMBINATION CHEMOTHERAPY;
DRUG APPROVAL;
DRUG CLASSIFICATION;
DRUG MARKETING;
DRUG MECHANISM;
DRUG POTENCY;
DRUG RESEARCH;
DRUG SAFETY;
DRUG TOLERABILITY;
DRUG WITHDRAWAL;
HEALTH CARE AVAILABILITY;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
LIVER TOXICITY;
MONOTHERAPY;
PRIORITY JOURNAL;
VIRUS RESISTANCE;
ANTI-HIV AGENTS;
CLINICAL TRIALS;
CYCLOHEXANES;
DRUG RESISTANCE, VIRAL;
HIV FUSION INHIBITORS;
HIV INFECTIONS;
HUMANS;
RECEPTORS, CCR5;
RECEPTORS, CXCR4;
TRIAZOLES;
|
|
EID: 33947722123
PISSN: 14741776
EISSN: 14741784
Source Type: Journal
DOI: 10.1038/nrd2294 Document Type: Article |
|
Times cited : (24)
|
|
References (0)
|
